MicroRNAs for osteosarcoma in the mouse: a meta-analysis

Junli Chang1,2, Min Yao1,2, Yimian Li1,2

  • 1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Oncotarget
|November 17, 2016
PubMed

Insights

MicroRNAs (miRNAs) show promise for treating osteosarcoma (OS) by suppressing tumor growth in mouse models. However, current research quality is low, necessitating rigorous animal studies before clinical application.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Osteosarcoma (OS) is a prevalent and aggressive bone cancer primarily affecting children and young adults.
  • MicroRNAs (miRNAs) are crucial gene regulators involved in cancer initiation and progression.

Purpose of the Study:

  • To evaluate the therapeutic potential of miRNAs for osteosarcoma (OS) prevention and treatment in mouse models.
  • To assess the methodological quality of existing miRNA-related osteosarcoma studies in animals.

Main Methods:

  • A systematic literature search was conducted across multiple databases (PubMed, Web of Science, Embase, etc.) up to May 10, 2016.
  • Thirty-six randomized controlled studies investigating miRNA effects on osteosarcoma in mice were included in a meta-analysis.
  • Pair-wise analysis was performed to assess the impact of miRNA manipulation on tumor progression.

Main Results:

  • Modulating miRNA expression—blocking oncogenic or restoring tumor-suppressive miRNAs—significantly inhibited osteosarcoma progression in vivo.
  • Tumor volume and weight were significantly reduced following miRNA-based interventions in mouse models.

Conclusions:

  • MicroRNAs represent promising therapeutic targets for osteosarcoma, with altered expression correction suppressing tumor growth in preclinical models.
  • The overall methodological quality of included studies was low, highlighting the need for more rigorous animal research before clinical translation.